Hypoxia, Therapeutic Resistance, and Sphingosine 1-Phosphate

Advances in Cancer Research

Volumn 117, Issue , 2013, Pages 117-141

  Cuvillier, Olivier ^a,b   Ader, Isabelle ^a,b   Bouquerel, Pierre ^a,b   Brizuela, Leyre ^a,b   Gstalder, Cécile ^a,b   Malavaud, Bernard ^a,b  

^a INSTITUT DE PHARMACOLOGIE ET DE BIOLOGIE STRUCTURALE   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

Angiogenesis; Chemotherapy; HIF; Hypoxia; Radiotherapy; Sphingolipids

Indexed keywords

ABC TRANSPORTER; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; SPHINGOSINE 1 PHOSPHATE;

ANGIOGENESIS; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER THERAPY; CELL CYCLE ARREST; CELL PROLIFERATION; CELL SURVIVAL; DNA DAMAGE; ENZYME ACTIVATION; HUMAN; HYPOXIA; INFLAMMATION; IONIZING RADIATION; KIDNEY CARCINOMA; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION; TISSUE OXYGENATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR VOLUME; UPREGULATION;

EID: 84871763530     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-394274-6.00005-4     Document Type: Chapter

References (159)

1. Ader I., Brizuela L., Bouquerel P., Malavaud B., Cuvillier O. Sphingosine kinase 1: A new modulator of hypoxia inducible factor 1alpha during hypoxia in human cancer cells. Cancer Research 2008, 68:8635-8642.
2. Ahmad M., Long J.S., Pyne N.J., Pyne S. The effect of hypoxia on lipid phosphate receptor and sphingosine kinase expression and mitogen-activated protein kinase signaling in human pulmonary smooth muscle cells. Prostaglandins & Other Lipid Mediators 2006, 79:278-286.
3. Alvarez S.E., Harikumar K.B., Hait N.C., Allegood J., Strub G.M., Kim E.Y., et al. Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature 2010, 465:1084-1088.
4. An W.G., Kanekal M., Simon M.C., Maltepe E., Blagosklonny M.V., Neckers L.M. Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature 1998, 392:405-408.
5. Anelli V., Gault C.R., Cheng A.B., Obeid L.M. Sphingosine Kinase 1 Is Up-regulated during Hypoxia in U87MG glioma cells: Role of hypoxia-inducible factors 1 and 2. The Journal of Biological Chemistry 2008, 283:3365-3375.
6. Arany Z., Huang L.E., Eckner R., Bhattacharya S., Jiang C., Goldberg M.A., et al. An essential role for p300/CBP in the cellular response to hypoxia. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:12969-12973.
7. Bell E.L., Klimova T.A., Eisenbart J., Moraes C.T., Murphy M.P., Budinger G.R., et al. The Qo site of the mitochondrial complex III is required for the transduction of hypoxic signaling via reactive oxygen species production. The Journal of Cell Biology 2007, 177:1029-1036.
8. Bonhoure E., Lauret A., Barnes D.J., Martin C., Malavaud B., Kohama T., et al. Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells. Leukemia 2008, 22:971-979.
9. Bonhoure E., Pchejetski D., Aouali N., Morjani H., Levade T., Kohama T., et al. Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1. Leukemia 2006, 20:95-102.
10. Bristow R.G., Hill R.P. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nature Reviews. Cancer 2008, 8:180-192.
11. Brizuela L., Dayon A., Doumerc N., Ader I., Golzio M., Izard J.C., et al. The sphingosine kinase-1 survival pathway is a molecular target for the tumor-suppressive tea and wine polyphenols in prostate cancer. The FASEB Journal 2010, 24:3882-3894.
12. Brugarolas J., Lei K., Hurley R.L., Manning B.D., Reiling J.H., Hafen E., et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes & Development 2004, 18:2893-2904.
13. Bruick R.K., McKnight S.L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001, 294:1337-1340.
14. Chae S.S., Paik J.H., Furneaux H., Hla T. Requirement for sphingosine 1-phosphate receptor-1 in tumor angiogenesis demonstrated by in vivo RNA interference. The Journal of Clinical Investigation 2004, 114:1082-1089.
15. Chandel N.S., Maltepe E., Goldwasser E., Mathieu C.E., Simon M.C., Schumacker P.T. Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:11715-11720.
16. Chandel N.S., McClintock D.S., Feliciano C.E., Wood T.M., Melendez J.A., Rodriguez A.M., et al. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1alpha during hypoxia: A mechanism of O2 sensing. The Journal of Biological Chemistry 2000, 275:25130-25138.
17. Chen L., Feng P., Li S., Long D., Cheng J., Lu Y., et al. Effect of hypoxia-inducible factor-1alpha silencing on the sensitivity of human brain glioma cells to doxorubicin and etoposide. Neurochemical Research 2009, 34:984-990.
18. Chen E.Y., Mazure N.M., Cooper J.A., Giaccia A.J. Hypoxia activates a platelet-derived growth factor receptor/phosphatidylinositol 3-kinase/Akt pathway that results in glycogen synthase kinase-3 inactivation. Cancer Research 2001, 61:2429-2433.
19. Cho S.Y., Lee H.J., Jeong S.J., Kim H.S., Chen C.Y., Lee E.O., et al. Sphingosine kinase 1 pathway is involved in melatonin-induced HIF-1alpha inactivation in hypoxic PC-3 prostate cancer cells. Journal of Pineal Research 2011, 51:87-93.
20. Cockman M.E., Masson N., Mole D.R., Jaakkola P., Chang G.W., Clifford S.C., et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. The Journal of Biological Chemistry 2000, 275:25733-25741.
21. Comerford K.M., Wallace T.J., Karhausen J., Louis N.A., Montalto M.C., Colgan S.P. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Research 2002, 62:3387-3394.
22. Condeelis J., Pollard J.W. Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006, 124:263-266.
23. Cosse J.P., Michiels C. Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Anti-Cancer Agents in Medicinal Chemistry 2008, 8:790-797.
24. Cuvillier O. Sphingosine in apoptosis signaling. Biochimica et Biophysica Acta 2002, 1585:153-162.
25. Cuvillier O. Sphingosine kinase-1-A potential therapeutic target in cancer. Anti-cancer Drugs 2007, 18:105-110.
26. Cuvillier O., Ader I., Bouquerel P., Brizuela L., Malavaud B., Mazerolles C., et al. Activation of Sphingosine Kinase-1 in cancer: Implications for therapeutic targeting. Current Molecular Pharmacology 2010, 3:53-65.
27. Cuvillier O., Edsall L., Spiegel S. Involvement of sphingosine in mitochondria-dependent Fas-induced apoptosis of type II Jurkat T cells. The Journal of Biological Chemistry 2000, 275:15691-15700.
28. Cuvillier O., Nava V.E., Murthy S.K., Edsall L.C., Levade T., Milstien S., et al. Sphingosine generation, cytochrome c release, and activation of caspase-7 in doxorubicin-induced apoptosis of MCF7 breast adenocarcinoma cells. Cell Death and Differentiation 2001, 8:162-171.
29. Cuvillier O., Pirianov G., Kleuser B., Vanek P.G., Coso O.A., Gutkind S., et al. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 1996, 381:800-803.
30. Daskalow K., Rohwer N., Raskopf E., Dupuy E., Kuhl A., Loddenkemper C., et al. Role of hypoxia-inducible transcription factor 1alpha for progression and chemosensitivity of murine hepatocellular carcinoma. Journal of molecular medicine (Berlin) 2010, 88:817-827.
31. Dayon A., Brizuela L., Martin C., Mazerolles C., Pirot N., Doumerc N., et al. Sphingosine kinase-1 is central to androgen-regulated prostate cancer growth and survival. PloS One 2009, 4:e8048.
32. Dejana E., Tournier-Lasserve E., Weinstein B.M. The control of vascular integrity by endothelial cell junctions: Molecular basis and pathological implications. Developmental Cell 2009, 16:209-221.
33. Ding Z., Yang L., Xie X., Xie F., Pan F., Li J., et al. Expression and significance of hypoxia-inducible factor-1 alpha and MDR1/P-glycoprotein in human colon carcinoma tissue and cells. Journal of Cancer Research and Clinical Oncology 2010, 136:1697-1707.
34. Du W., Takuwa N., Yoshioka K., Okamoto Y., Gonda K., Sugihara K., et al. S1P(2), the G protein-coupled receptor for sphingosine-1-phosphate, negatively regulates tumor angiogenesis and tumor growth in vivo in mice. Cancer Research 2010, 70:772-781.
35. Du J., Xu R., Hu Z., Tian Y., Zhu Y., Gu L., et al. PI3K and ERK-induced Rac1 activation mediates hypoxia-induced HIF-1alpha expression in MCF-7 breast cancer cells. PloS One 2011, 6:e25213.
36. Ema M., Taya S., Yokotani N., Sogawa K., Matsuda Y., Fujii-Kuriyama Y. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:4273-4278.
37. Epstein A.C., Gleadle J.M., McNeill L.A., Hewitson K.S., O'Rourke J., Mole D.R., et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001, 107:43-54.
38. Flamme I., Frohlich T., von Reutern M., Kappel A., Damert A., Risau W. HRF, a putative basic helix-loop-helix-PAS-domain transcription factor is closely related to hypoxia-inducible factor-1 alpha and developmentally expressed in blood vessels. Mechanisms of Development 1997, 63:51-60.
39. Flugel D., Gorlach A., Michiels C., Kietzmann T. Glycogen synthase kinase 3 phosphorylates hypoxia-inducible factor 1alpha and mediates its destabilization in a VHL-independent manner. Molecular and Cellular Biology 2007, 27:3253-3265.
40. Fokas E., Im J.H., Hill S., Yameen S., Stratford M., Beech J., et al. Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature. Cancer Research 2012, 72:239-248.
41. French K.J., Schrecengost R.S., Lee B.D., Zhuang Y., Smith S.N., Eberly J.L., et al. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Research 2003, 63:5962-5969.
42. French K.J., Upson J.J., Keller S.N., Zhuang Y., Yun J.K., Smith C.D. Antitumor activity of sphingosine kinase inhibitors. The Journal of Pharmacology and Experimental Therapeutics 2006, 318:596-603.
43. Galanis A., Pappa A., Giannakakis A., Lanitis E., Dangaj D., Sandaltzopoulos R. Reactive oxygen species and HIF-1 signalling in cancer. Cancer Letters 2008, 266:12-20.
44. Gao N., Ding M., Zheng J.Z., Zhang Z., Leonard S.S., Liu K.J., et al. Vanadate-induced expression of hypoxia-inducible factor 1 alpha and vascular endothelial growth factor through phosphatidylinositol 3-kinase/Akt pathway and reactive oxygen species. The Journal of Biological Chemistry 2002, 277:31963-31971.
45. Garcia J.G., Liu F., Verin A.D., Birukova A., Dechert M.A., Gerthoffer W.T., et al. Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. The Journal of Clinical Investigation 2001, 108:689-701.
46. Goel S., Duda D.G., Xu L., Munn L.L., Boucher Y., Fukumura D., et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiological Reviews 2011, 91:1071-1121.
47. Gonzalez E., Kou R., Michel T. Rac1 modulates sphingosine 1-phosphate-mediated activation of phosphoinositide 3-kinase/Akt signaling pathways in vascular endothelial cells. The Journal of Biological Chemistry 2006, 281:3210-3216.
48. Gordan J.D., Bertout J.A., Hu C.J., Diehl J.A., Simon M.C. HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 2007, 11:335-347.
49. Gordan J.D., Lal P., Dondeti V.R., Letrero R., Parekh K.N., Oquendo C.E., et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 2008, 14:435-446.
50. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nature Reviews. Cancer 2002, 2:48-58.
51. Guzy R.D., Hoyos B., Robin E., Chen H., Liu L., Mansfield K.D., et al. Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metabolism 2005, 1:401-408.
52. Hait N.C., Allegood J., Maceyka M., Strub G.M., Harikumar K.B., Singh S.K., et al. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science 2009, 325:1254-1257.
53. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364.
54. Harris A.L. Hypoxia-A key regulatory factor in tumour growth. Nature Reviews. Cancer 2002, 2:38-47.
55. Hashizume H., Baluk P., Morikawa S., McLean J.W., Thurston G., Roberge S., et al. Openings between defective endothelial cells explain tumor vessel leakiness. The American Journal of Pathology 2000, 156:1363-1380.
56. Heikkila M., Pasanen A., Kivirikko K.I., Myllyharju J. Roles of the human hypoxia-inducible factor (HIF)-3alpha variants in the hypoxia response. Cellular and Molecular Life Sciences 2011, 68:3885-3901.
57. Herr B., Zhou J., Werno C., Menrad H., Namgaladze D., Weigert A., et al. The supernatant of apoptotic cells causes transcriptional activation of hypoxia-inducible factor-1alpha in macrophages via sphingosine-1-phosphate and transforming growth factor-beta. Blood 2009, 114:2140-2148.
58. Hickey M.M., Simon M.C. Regulation of angiogenesis by hypoxia and hypoxia-inducible factors. Current Topics in Developmental Biology 2006, 76:217-257.
59. Hogenesch J.B., Chan W.K., Jackiw V.H., Brown R.C., Gu Y.Z., Pray-Grant M., et al. Characterization of a subset of the basic-helix-loop-helix-PAS superfamily that interacts with components of the dioxin signaling pathway. The Journal of Biological Chemistry 1997, 272:8581-8593.
60. Hu C.J., Wang L.Y., Chodosh L.A., Keith B., Simon M.C. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Molecular and Cellular Biology 2003, 23:9361-9374.
61. Hughes J.E., Srinivasan S., Lynch K.R., Proia R.L., Ferdek P., Hedrick C.C. Sphingosine-1-phosphate induces an antiinflammatory phenotype in macrophages. Circulation Research 2008, 102:950-958.
62. Ivan M., Kondo K., Yang H., Kim W., Valiando J., Ohh M., et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing. Science 2001, 292:464-468.
63. Iwai K., Yamanaka K., Kamura T., Minato N., Conaway R.C., Conaway J.W., et al. Identification of the von Hippel-Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:12436-12441.
64. Jaakkola P., Mole D.R., Tian Y.M., Wilson M.I., Gielbert J., Gaskell S.J., et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001, 292:468-472.
65. Jain R.K. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
66. Kaelin W.G. Kidney cancer: Now available in a new flavor. Cancer Cell 2008, 14:423-424.
67. Kaelin W.G., Ratcliffe P.J. Oxygen sensing by metazoans: The central role of the HIF hydroxylase pathway. Molecular Cell 2008, 30:393-402.
68. Kapitonov D., Allegood J.C., Mitchell C., Hait N.C., Almenara J.A., Adams J.K., et al. Targeting sphingosine kinase 1 inhibits Akt signaling, induces apoptosis, and suppresses growth of human glioblastoma cells and xenografts. Cancer Research 2009, 69:6915-6923.
69. Karliner J.S., Honbo N., Summers K., Gray M.O., Goetzl E.J. The lysophospholipids sphingosine-1-phosphate and lysophosphatidic acid enhance survival during hypoxia in neonatal rat cardiac myocytes. Journal of Molecular and Cellular Cardiology 2001, 33:1713-1717.
70. Keith B., Johnson R.S., Simon M.C. HIF1alpha and HIF2alpha: Sibling rivalry in hypoxic tumour growth and progression. Nature Reviews. Cancer 2012, 12:9-22.
71. Klimova T., Chandel N.S. Mitochondrial complex III regulates hypoxic activation of HIF. Cell Death and Differentiation 2008, 15:660-666.
72. Koh M.Y., Darnay B.G., Powis G. Hypoxia-associated factor, a novel E3-ubiquitin ligase, binds and ubiquitinates hypoxia-inducible factor 1alpha, leading to its oxygen-independent degradation. Molecular and Cellular Biology 2008, 28:7081-7095.
73. Koshikawa N., Hayashi J., Nakagawara A., Takenaga K. Reactive oxygen species-generating mitochondrial DNA mutation up-regulates hypoxia-inducible factor-1alpha gene transcription via phosphatidylinositol 3-kinase-Akt/protein kinase C/histone deacetylase pathway. The Journal of Biological Chemistry 2009, 284:33185-33194.
74. LaMontagne K., Littlewood-Evans A., Schnell C., O'Reilly T., Wyder L., Sanchez T., et al. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Research 2006, 66:221-231.
75. Lappano R., Maggiolini M. G protein-coupled receptors: Novel targets for drug discovery in cancer. Nature Reviews. Drug Discovery 2011, 10:47-60.
76. Lee M.J., Thangada S., Claffey K.P., Ancellin N., Liu C.H., Kluk M., et al. Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell 1999, 99:301-312.
77. Lewis C.E., Pollard J.W. Distinct role of macrophages in different tumor microenvironments. Cancer Research 2006, 66:605-612.
78. Li Q.F., Huang W.R., Duan H.F., Wang H., Wu C.T., Wang L.S. Sphingosine kinase-1 mediates BCR/ABL-induced upregulation of Mcl-1 in chronic myeloid leukemia cells. Oncogene 2007, 26:7904-7908.
79. Liao D., Johnson R.S. Hypoxia: A key regulator of angiogenesis in cancer. Cancer Metastasis Reviews 2007, 26:281-290.
80. Lisztwan J., Imbert G., Wirbelauer C., Gstaiger M., Krek W. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes & Development 1999, 13:1822-1833.
81. Liu L.Z., Hu X.W., Xia C., He J., Zhou Q., Shi X., et al. Reactive oxygen species regulate epidermal growth factor-induced vascular endothelial growth factor and hypoxia-inducible factor-1alpha expression through activation of AKT and P70S6K1 in human ovarian cancer cells. Free Radical Biology & Medicine 2006, 41:1521-1533.
82. Liu L., Ning X., Sun L., Zhang H., Shi Y., Guo C., et al. Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced chemoresistance in gastric cancer. Cancer Science 2008, 99:121-128.
83. Liu H., Sugiura M., Nava V.E., Edsall L.C., Kono K., Poulton S., et al. Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. The Journal of Biological Chemistry 2000, 275:19513-19520.
84. Lu X., Kang Y. Hypoxia and hypoxia-inducible factors: Master regulators of metastasis. Clinical Cancer Research 2010, 16:5928-5935.
85. Majmundar A.J., Wong W.J., Simon M.C. Hypoxia-inducible factors and the response to hypoxic stress. Molecular Cell 2010, 40:294-309.
86. Makino Y., Kanopka A., Wilson W.J., Tanaka H., Poellinger L. Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3alpha locus. The Journal of Biological Chemistry 2002, 277:32405-32408.
87. Makino Y., Uenishi R., Okamoto K., Isoe T., Hosono O., Tanaka H., et al. Transcriptional up-regulation of inhibitory PAS domain protein gene expression by hypoxia-inducible factor 1 (HIF-1): A negative feedback regulatory circuit in HIF-1-mediated signaling in hypoxic cells. The Journal of Biological Chemistry 2007, 282:14073-14082.
88. Mantovani A., Schioppa T., Porta C., Allavena P., Sica A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Reviews 2006, 25:315-322.
89. Masson N., Willam C., Maxwell P.H., Pugh C.W., Ratcliffe P.J. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. The EMBO Journal 2001, 20:5197-5206.
90. Melillo G. Hypoxia-inducible factor 1 inhibitors. Methods in Enzymology 2007, 435:385-402.
91. Michaud M.D., Robitaille G.A., Gratton J.P., Richard D.E. Sphingosine-1-phosphate: A novel nonhypoxic activator of hypoxia-inducible factor-1 in vascular cells. Arteriosclerosis, Thrombosis, and Vascular Biology 2009, 29:902-908.
92. Michel M.C., Mulders A.C., Jongsma M., Alewijnse A.E., Peters S.L. Vascular effects of sphingolipids. Acta Paediatrica. Supplement 2007, 96:44-48.
93. Milosevic M., Fyles A., Hedley D., Hill R. The human tumor microenvironment: Invasive (needle) measurement of oxygen and interstitial fluid pressure. Seminars in Radiation Oncology 2004, 14:249-258.
94. Milosevic M., Warde P., Menard C., Chung P., Toi A., Ishkanian A., et al. Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer. Clinical Cancer Research 2012, 18:2108-2114.
95. Moeller B.J., Richardson R.A., Dewhirst M.W. Hypoxia and radiotherapy: Opportunities for improved outcomes in cancer treatment. Cancer Metastasis Reviews 2007, 26:241-248.
96. Mottet D., Dumont V., Deccache Y., Demazy C., Ninane N., Raes M., et al. Regulation of hypoxia-inducible factor-1alpha protein level during hypoxic conditions by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3beta pathway in HepG2 cells. The Journal of Biological Chemistry 2003, 278:31277-31285.
97. Mylonis I., Chachami G., Samiotaki M., Panayotou G., Paraskeva E., Kalousi A., et al. Identification of MAPK phosphorylation sites and their role in the localization and activity of hypoxia-inducible factor-1alpha. The Journal of Biological Chemistry 2006, 281:33095-33106.
98. Nava V.E., Cuvillier O., Edsall L.C., Kimura K., Milstien S., Gelmann E.P., et al. Sphingosine enhances apoptosis of radiation-resistant prostate cancer cells. Cancer Research 2000, 60:4468-4474.
99. Nava V.E., Hobson J.P., Murthy S., Milstien S., Spiegel S. Sphingosine kinase type 1 promotes estrogen-dependent tumorigenesis of breast cancer MCF-7 cells. Experimental Cell Research 2002, 281:115-127.
100. Ohh M., Park C.W., Ivan M., Hoffman M.A., Kim T.Y., Huang L.E., et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nature Cell Biology 2000, 2:423-427.
101. Pappu R., Schwab S.R., Cornelissen I., Pereira J.P., Regard J.B., Xu Y., et al. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science 2007, 316:295-298.
102. Patiar S., Harris A.L. Role of hypoxia-inducible factor-1alpha as a cancer therapy target. Endocrine-Related Cancer 2006, 13(Suppl. 1):S61-S75.
103. Paugh S.W., Paugh B.S., Rahmani M., Kapitonov D., Almenara J.A., Kordula T., et al. A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia. Blood 2008, 112:1382-1391.
104. Pchejetski D., Boehler T., Brizuela L., Sauer L., Doumerc N., Golzio M., et al. FTY720 (Fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1. Cancer Research 2010, 70:8651-8661.
105. Pchejetski D., Doumerc N., Golzio M., Naymark M., Teissie J., Kohama T., et al. Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models. Molecular Cancer Therapeutics 2008, 7:1836-1845.
106. Pchejetski D., Golzio M., Bonhoure E., Calvet C., Doumerc N., Garcia V., et al. Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. Cancer Research 2005, 65:11667-11675.
107. Pitson S.M. Regulation of sphingosine kinase and sphingolipid signaling. Trends in Biochemical Sciences 2011, 36:97-107.
108. Pore N., Gupta A.K., Cerniglia G.J., Jiang Z., Bernhard E.J., Evans S.M., et al. Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: Implications for radiotherapy. Cancer Research 2006, 66:9252-9259.
109. Poyton R.O., Ball K.A., Castello P.R. Mitochondrial generation of free radicals and hypoxic signaling. Trends in Endocrinology and Metabolism 2009, 20:332-340.
110. Pyne N.J., Pyne S. Sphingosine 1-phosphate and cancer. Nature Reviews. Cancer 2010, 10:489-503.
111. Pyne S., Pyne N.J. Translational aspects of sphingosine 1-phosphate biology. Trends in Molecular Medicine 2011, 17:463-472.
112. Raval R.R., Lau K.W., Tran M.G., Sowter H.M., Mandriota S.J., Li J.L., et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Molecular and Cellular Biology 2005, 25:5675-5686.
113. Richard D.E., Berra E., Gothie E., Roux D., Pouyssegur J. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. The Journal of Biological Chemistry 1999, 274:32631-32637.
114. Rodriguez-Jimenez F.J., Moreno-Manzano V. Modulation of hypoxia-inducible factors (HIF) from an integrative pharmacological perspective. Cellular and Molecular Life Sciences 2012, 69:519-534.
115. Rohwer N., Cramer T. Hypoxia-mediated drug resistance: Novel insights on the functional interaction of HIFs and cell death pathways. Drug Resistance Updates 2011, 14:191-201.
116. Rosen H., Gonzalez-Cabrera P.J., Sanna M.G., Brown S. Sphingosine 1-phosphate receptor signaling. Annual Review of Biochemistry 2009, 78:743-768.
117. Sanchez T., Skoura A., Wu M.T., Casserly B., Harrington E.O., Hla T. Induction of vascular permeability by the sphingosine-1-phosphate receptor-2 (S1P2R) and its downstream effectors ROCK and PTEN. Arteriosclerosis, Thrombosis, and Vascular Biology 2007, 27:1312-1318.
118. Schnitzer S.E., Weigert A., Zhou J., Brune B. Hypoxia enhances sphingosine kinase 2 activity and provokes sphingosine-1-phosphate-mediated chemoresistance in A549 lung cancer cells. Molecular Cancer Research 2009, 7:393-401.
119. Schwalm S., Doll F., Romer I., Bubnova S., Pfeilschifter J., Huwiler A. Sphingosine kinase-1 is a hypoxia-regulated gene that stimulates migration of human endothelial cells. Biochemical and Biophysical Research Communications 2008, 368:1020-1025.
120. Semenza G.L. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010, 29:625-634.
121. Semenza G.L. Oxygen sensing, homeostasis, and disease. The New England Journal of Medicine 2011, 365:537-547.
122. Semenza G.L. Hypoxia-inducible factors: Mediators of cancer progression and targets for cancer therapy. Trends in Pharmacological Sciences 2012, 33:207-214.
123. Simon M.C. Mitochondrial reactive oxygen species are required for hypoxic HIF alpha stabilization. Advances in Experimental Medicine and Biology 2006, 588:165-170.
124. Skoura A., Sanchez T., Claffey K., Mandala S.M., Proia R.L., Hla T. Essential role of sphingosine 1-phosphate receptor 2 in pathological angiogenesis of the mouse retina. The Journal of Clinical Investigation 2007, 117:2506-2516.
125. Skuli N., Monferran S., Delmas C., Lajoie-Mazenc I., Favre G., Toulas C., et al. Activation of RhoB by hypoxia controls hypoxia-inducible factor-1alpha stabilization through glycogen synthase kinase-3 in U87 glioblastoma cells. Cancer Research 2006, 66:482-489.
126. Sodhi A., Montaner S., Miyazaki H., Gutkind J.S. MAPK and Akt act cooperatively but independently on hypoxia inducible factor-1alpha in rasV12 upregulation of VEGF. Biochemical and Biophysical Research Communications 2001, 287:292-300.
127. Spiegel S., Milstien S. Functions of the multifaceted family of sphingosine kinases and some close relatives. The Journal of Biological Chemistry 2007, 282:2125-2129.
128. Strub G.M., Maceyka M., Hait N.C., Milstien S., Spiegel S. Extracellular and intracellular actions of sphingosine-1-phosphate. Advances in Experimental Medicine and Biology 2010, 688:141-155.
129. Sullivan R., Graham C.H. Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Reviews 2007, 26:319-331.
130. Sullivan R., Graham C.H. Hypoxia prevents etoposide-induced DNA damage in cancer cells through a mechanism involving hypoxia-inducible factor 1. Molecular Cancer Therapeutics 2009, 8:1702-1713.
131. Taha T.A., Osta W., Kozhaya L., Bielawski J., Johnson K.R., Gillanders W.E., et al. Down-regulation of sphingosine kinase-1 by DNA damage: Dependence on proteases and p53. The Journal of Biological Chemistry 2004, 279:20546-20554.
132. Talks K.L., Turley H., Gatter K.C., Maxwell P.H., Pugh C.W., Ratcliffe P.J., et al. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. The American Journal of Pathology 2000, 157:411-421.
133. Tanimoto K., Makino Y., Pereira T., Poellinger L. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. The EMBO Journal 2000, 19:4298-4309.
134. Tao R., Zhang J., Vessey D.A., Honbo N., Karliner J.S. Deletion of the sphingosine kinase-1 gene influences cell fate during hypoxia and glucose deprivation in adult mouse cardiomyocytes. Cardiovascular Research 2007, 74:56-63.
135. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
136. Tian H., McKnight S.L., Russell D.W. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes & Development 1997, 11:72-82.
137. Tredan O., Galmarini C.M., Patel K., Tannock I.F. Drug resistance and the solid tumor microenvironment. Journal of the National Cancer Institute 2007, 99:1441-1454.
138. Vaupel P. The role of hypoxia-induced factors in tumor progression. The Oncologist 2004, 9(Suppl. 5):10-17.
139. Vaupel P., Mayer A. Hypoxia in cancer: Significance and impact on clinical outcome. Cancer Metastasis Reviews 2007, 26:225-239.
140. Visentin B., Vekich J.A., Sibbald B.J., Cavalli A.L., Moreno K.M., Matteo R.G., et al. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 2006, 9:225-238.
141. Wacker B.K., Park T.S., Gidday J.M. Hypoxic preconditioning-induced cerebral ischemic tolerance: Role of microvascular sphingosine kinase 2. Stroke 2009, 40:3342-3348.
142. Wang V., Davis D.A., Haque M., Huang L.E., Yarchoan R. Differential gene up-regulation by hypoxia-inducible factor-1alpha and hypoxia-inducible factor-2alpha in HEK293T cells. Cancer Research 2005, 65:3299-3306.
143. Wang G.L., Jiang B.H., Rue E.A., Semenza G.L. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proceedings of the National Academy of Sciences of the United States of America 1995, 92:5510-5514.
144. Wartenberg M., Ling F.C., Muschen M., Klein F., Acker H., Gassmann M., et al. Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species. The FASEB Journal 2003, 17:503-505.
145. Weigert A., Tzieply N., von Knethen A., Johann A.M., Schmidt H., Geisslinger G., et al. Tumor cell apoptosis polarizes macrophages role of sphingosine-1-phosphate. Molecular Biology of the Cell 2007, 18:3810-3819.
146. Weis N., Weigert A., von Knethen A., Brune B. Heme oxygenase-1 contributes to an alternative macrophage activation profile induced by apoptotic cell supernatants. Molecular Biology of the Cell 2009, 20:1280-1288.
147. Wiesener M.S., Jurgensen J.S., Rosenberger C., Scholze C.K., Horstrup J.H., Warnecke C., et al. Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs. The FASEB Journal 2003, 17:271-273.
148. Wilson W.R., Hay M.P. Targeting hypoxia in cancer therapy. Nature Reviews. Cancer 2011, 11:393-410.
149. Winkler F., Kozin S.V., Tong R.T., Chae S.S., Booth M.F., Garkavtsev I., et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004, 6:553-563.
150. Wirthner R., Wrann S., Balamurugan K., Wenger R.H., Stiehl D.P. Impaired DNA double-strand break repair contributes to chemoresistance in HIF-1 alpha-deficient mouse embryonic fibroblasts. Carcinogenesis 2008, 29:2306-2316.
151. Wojciak J.M., Zhu N., Schuerenberg K.T., Moreno K., Shestowsky W.S., Hiraiwa M., et al. The crystal structure of sphingosine-1-phosphate in complex with a Fab fragment reveals metal bridging of an antibody and its antigen. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:17717-17722.
152. Yester J.W., Tizazu E., Harikumar K.B., Kordula T. Extracellular and intracellular sphingosine-1-phosphate in cancer. Cancer Metastasis Reviews 2011, 30:577-597.
153. Yotnda P., Wu D., Swanson A.M. Hypoxic tumors and their effect on immune cells and cancer therapy. Methods in Molecular Biology 2010, 651:1-29.
154. Yu F., White S.B., Zhao Q., Lee F.S. HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:9630-9635.
155. Yun J.K., Kester M. Regulatory role of sphingomyelin metabolites in hypoxia-induced vascular smooth muscle cell proliferation. Archives of Biochemistry and Biophysics 2002, 408:78-86.
156. Zhang J., Honbo N., Goetzl E.J., Chatterjee K., Karliner J.S., Gray M.O. Signals from type 1 sphingosine 1-phosphate receptors enhance adult mouse cardiac myocyte survival during hypoxia. American Journal of Physiology. Heart and Circulatory Physiology 2007, 293:H3150-H3158.
157. Zhang H., Li W., Sun S., Yu S., Zhang M., Zou F. Inhibition of sphingosine kinase 1 suppresses proliferation of glioma cells under hypoxia by attenuating activity of extracellular signal-regulated kinase. Cell Proliferation 2012, 45:167-175.
158. Zhou Q., Liu L.Z., Fu B., Hu X., Shi X., Fang J., et al. Reactive oxygen species regulate insulin-induced VEGF and HIF-1alpha expression through the activation of p70S6K1 in human prostate cancer cells. Carcinogenesis 2007, 28:28-37.
159. Zhu H., Chen X.P., Luo S.F., Guan J., Zhang W.G., Zhang B.X. Involvement of hypoxia-inducible factor-1-alpha in multidrug resistance induced by hypoxia in HepG2 cells. Journal of Experimental & Clinical Cancer Research 2005, 24:565-574.